A breakthrough in pancreatic cancer research has emerged from a study led by Dr. Mariano Barbacid and his team at Spain’s National Cancer Research Center (CNIO). The research, published in the Proceedings of the National Academy of Sciences (PNAS), details a novel treatment that completely eliminated pancreatic tumors in preclinical mouse models. The therapy combines three drugs—afatinib, daraxonrasib, and an experimental compound called SD36—which collectively attacked the cancer from multiple biological pathways.
What the Study Found
The study focused on pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer. This type of cancer is notoriously resistant to treatment, often developing alternative growth mechanisms when a single pathway is blocked. The triple-drug regimen bypassed this resistance by simultaneously targeting three distinct molecular pathways. In mouse trials, the approach led to the complete and durable removal of tumors without significant side effects, including maintaining tissue integrity and normal blood cell counts.
Dr. Barbacid emphasized that while the results are unprecedented, the therapy is not yet ready for human trials. “Although experimental results like those described here have never been obtained before, we are still not in a position to carry out clinical trials with the triple therapy,” he stated in a CNIO press release.
Limitations and Next Steps
The research remains in the preclinical phase, with no indication of human testing timelines. The study’s authors caution that while the combination showed promise in mice, translating these findings to humans will require further investigation. Pancreatic cancer remains one of the deadliest cancers, with a global 5-year survival rate of just 10%. Current treatments often fail due to rapid resistance and severe toxicity.
Experts note that combination therapies like this one are challenging to develop, as they must balance efficacy with safety. The CNIO team’s approach, which avoided the typical toxic side effects seen in aggressive treatments, represents a critical step forward. However, the path to clinical application is likely to be lengthy, involving rigorous testing to ensure both effectiveness and tolerability in human patients.
The study underscores the importance of multi-pronged strategies in oncology, particularly for cancers with high mortality rates. Researchers hope that this work will inspire further exploration of combination therapies that target cancer’s adaptability.
